FDA inspection
Shaanxi Hanjiang Pharmaceutical Group Co., Ltd (Gaoxin site): FDA inspection ending Sep 21, 2023
FDA inspection 1218824 · Voluntary Action Indicated (VAI) · Hanzhong
Key facts
| Inspection ID | 1218824 |
|---|---|
| Firm | Shaanxi Hanjiang Pharmaceutical Group Co., Ltd (Gaoxin site) |
| FEI number | 3003011617 |
| Address | Hanzhong Hi-Tech, No. 3 Lianhua Road; Industries Development Zone |
| City | Hanzhong |
| Country | China |
| Fiscal year | 2023 |
| Inspection end date | Sep 21, 2023 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Monitoring of Marketed Animal Drugs, Feed, and Devices |
| Product type | Veterinary |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data